Global Proteomics Market
Proteomics Market size was over USD 35.34 billion in 2024 and is poised to reach USD 187.84 billion by the end of 2037, growing at around 13.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of proteomics is assessed at USD 39.21 billion.
The expansion of the market is being driven by the rise in chronic diseases such as cancer, diabetes, CVDs, respiratory disorders, CKD, and others on a global scale. It is also feasible to locate anticancer drugs and modify cancer treatment with oncoprotein. Proteomics is becoming more and more necessary due to the utilization of oncoproteins in the brain, colon, breast, rectum, prostate, and other tissues for cancer treatment. Proteomics can be used to find new therapeutic options as well as diagnose cancer. Almost one in six deaths in 2020, or over 10 million deaths, were related to cancer, according to the WHO.
In addition to these, the growing demand for personalized medicines and better diagnostics to treat targeted diseases, as well as the disproportionate incidence of target diseases, is providing a major driving force behind the increased demand for proteomics. Prophylactics are becoming dominant in the medical sector. The high accuracy and susceptibility of mass spectrometric study of proteomes are well matched for the integration of proteomics into precision medicine. The future of personalized medicine is based on using proteomics in the clinic, according to NCBI. The efficient application of personal proteomics to diagnose and treat conditions depends upon the appropriate translation of scientific findings into medical practice. Precision medicine is aimed at ensuring that each individual patient gets the best possible outcome by being more precisely and effectively matched to the most appropriate treatment regimen. Early diagnosis of the disease status and severity, as well as improved patient outcomes through a rapid proteomic examination of easily accessible tissue samples enables medical staff to respond more quickly in case of emergency. Due to the advantages of personalized proteomics, there has been a rapid growth in this proteomics market.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.6% |
|
Base Year Market Size (2024) |
USD 35.34 billion |
|
Forecast Year Market Size (2037) |
USD 187.84 billion |
|
Regional Scope |
|
Component (Instruments, Reagents, Software & Services)
The reagent segment in the proteomics market is expected to grow at a substantial CAGR of 13.4% till 2037. The growth of the segment can be attributed to the fact that reagents and consumables are in high demand due to the extensive use of kits, chemicals, strips, reagents & consumables, and other materials for the analysis of various biological samples in research labs, academic institutions, and other settings. High-quality chemical reagents are in high demand since proteomics research is complex and multidisciplinary. Mass spectrometry (MS)-based proteomics research has made use of novel chemical agents and methodologies. The goal of the synthesis of many chemical substances, including peptides and proteins, is to covalently bind them to biomolecules.
Application (Clinical Diagnostics, Drug Discovery)
Proteomics market from the drug discovery segment is expected to have a CAGR of 13.9% over the projected time frame. The drug discovery category is expected to grow at the fastest rate over the projected period. The growth of this market may be ascribed to the advancement of structure-based drug design, heightened focus on creating customized medications, and greater financial support for these initiatives. Proteomics technologies also offer a method to show early in a drug discovery programme, which helps the segment grow by saving pharmaceutical companies a lot of money and eventually helping patients and healthcare systems.
Our in-depth analysis of the global market includes the following segments:
|
Component |
|
|
Application |
|
|
End-User |
|
North American Market Forecast
The proteomics market in North America is poised to dominate 43% revenue share by 2037, growing at a CAGR of 13.9% during the forecast period. The market for proteomics products is growing as bispecific antibody conjugates and protein therapies become more widely available in North America for the purpose of treating and diagnosing diseases. Ten ADCs have already achieved FDA approval in the US, while over 90 ADCs are undergoing clinical development worldwide. A number of clinical indications that recently received approval for recombinant protein therapy include cancer, autoimmunity/inflammation, exposure to infectious agents, and hereditary illnesses. Proteomics is finding widespread use in antibody-drug conjugates and protein therapies in North America, which is driving up demand for proteomics products and propelling the market's quick expansion.
Europe Market Statistics
The Europe proteomics market is estimated to expand at a CAGR of 13.2% through 2037. The demand for the market is boosted by technical improvements, government support for proteomics, and Europe's growing research and expenditure. The rising prevalence of chronic illnesses like cancer, heart disease, respiratory conditions, and other conditions is also driving up market growth in Europe. The World Health Organization estimates that 60 million people in the European Region or 10.3% of men and 9.6% of women over the age of 25 have diabetes. Diabetes is growing more common in the European Region throughout all age groups, mainly due to increases in overweight and obesity, poor diets, and inactivity. These proteomics benefits are propelling the industry ahead.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?